Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

121.04 +0.02 (+0.02%)
Official Closing Price Updated: 7:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
46 47 Next >
Leading Data Analytics Company Vizlib Gains ISO 27001 Certification
About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the... 
Via PRUnderground
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever
These stocks are all trading close to their 52-week lows. 
Via The Motley Fool
Novartis (NVS) Q3 2022 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff
The spinoff will help Novartis become a "pure-play" innovative medicines giant, the company says. 
Via Investor's Business Daily
Novartis Clocks 4% Drop In Quarterly Sales, Once Again Perks Up Sandoz Earnings Outlook
Via Benzinga
Earnings Scheduled For October 25, 2022
Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter. 
Via Benzinga
Novartis Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bullish stance on Novartis. Looking at options history for Novartis (NYSE:NVS) we detected 21 strange trades. 
Via Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Twitter Considers Crypto Wallet, Geopolitical Woes To Keep Tesla Shares Volatile, Juul Explores Possible Bailout: Top Stories Tuesday, Oct. 25
Benzinga 
Via Benzinga
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
US Stock Futures Down; Big Tech Earnings In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the... 
Via Benzinga
Recap: Novartis Q3 Earnings
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 25, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings Novartis beat estimated earnings by... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Novartis Experimental Drug Shows Meaningful Superiority Over Previous Treatment In Rare Blood Disorder
Novartis AG's (NYSE: NVS) investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH).  
Via Benzinga
Alcon: Take A Look At Vision Care
Alcon AG is a global provider of ophthalmic surgery and vision care products. We have a favorable view of the company’s market position and product pipeline, and note that sales growth has outpaced... 
Via Talk Markets
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. 
Via Benzinga
Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022
Via Magic PR
Global Topical Pain Relief Gel Industry Size,Chain Research Report 2022-2028:Johnson & Johnson, Novartis, GlaxoSmithKline
Global Topical Pain Relief Gel Industry Research Report, Growth Trends and Competitive Analysis 2022-2028 
Via SBWire
Topics Economy
Biden Asked OPEC+ To Delay Output Decision, Elon Musk Faces Federal Probe Over Twitter Deal, Netflix Ad-Supported Plan: Top Stories Friday, Oct. 14
Reuters Twitter Says Elon Musk Under Federal Probe Over $44B Twitter Deal, In Court Filing 
Via Benzinga
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
Bone Cancer Market Overview, Industry Top Manufactures, Size, Growth Rate 2022- 2028:Amgen, Baxter, Bayer
Bone Cancer Market - The new report on the global Bone Cancer Market comes out as an extremely useful resource that helpsplayers to gain a competitive edge over their toughest competitors. It can be... 
Via SBWire
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Via Benzinga
2 Cathie Wood Stocks That Are Beating the Market This Year
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
Got $5,000? These 2 Stocks Are Bargain Buys Right Now
Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you. 
Via The Motley Fool
European Drug Makers Say Higher Energy Costs Eating Margins: Report
Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. 
Via Benzinga
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
Eli Lilly (LLY) shares rallied 4.9% in the last trading session to close at $310.87. This move can be attributable to notable volume with a higher number of shares being traded than in a typical... 
Via Talk Markets
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback